A new antidepressive drug (Doxepin) was tried in 17 in-patient (8 with endogenous depression, 7 with psychoneurotic depression and 2 with involutive depression). The duration of the treatment varied between 10 to 42 pays. The maximal dosis varied between 125 and 300 mg daily per os. Clinical evaluation was made every week regarding the symptomatology and the spontaneous side-effects referred by the patients. Laboratorial controls (leucocitometry, hematocrit, glutamic-oxalacetic transaminase, urea and albuminuria) were made before, during and after the treatment. The authors conclude: a) the side-affects did not interfere with the treatment; b) the laboratorial tests showed no significant changes; c) antidepressive effect was evidenced in 82,7% and remission in 52,9% of the cases; d) the psychoneurotic depression was the more susceptible to the treatment.